We are live on ! Find out more
Stempoint Capital

Stempoint Capital Portfolio holdings

AUM $560M Turnover 64.34%
1-Year Est. Return 146.87%
This Fund
S&P 500
This Quarter Est. Return
+5.16%
1 Year Est. Return
+146.87%
3 Year Est. Return
+725.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
+$66.6M
Cap. Flow
+$95.5M
Cap. Flow %
23.85%
Top 10 Hldgs %
50.8%
Holding
80
New
26
Increased
21
Reduced
6
Closed
26
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.3 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.3 years

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$19.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$15.5M
3
NUVL icon
Nuvalent
NUVL
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$12.7M
5
ALKS icon
Alkermes
ALKS
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.15%
2 Miscellaneous 0.46%
3 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SNDX icon
1
Syndax Pharmaceuticals
SNDX
$785M
$38M 9.48%
2,872,601
+1,141,410
+66% +$19.5M
2023 Q4
4 quarters
ROIV icon
2
Roivant Sciences
ROIV
$28B
$32.1M 8.01%
2,712,778
-57,041
-2% -$674K
2023 Q4
4 quarters
IMVT icon
3
Immunovant
IMVT
$6.57B
$27.7M 6.92%
1,118,508
+447,507
+67% +$12.7M
2023 Q4
4 quarters
MRUS icon
4
DELISTED
Merus
MRUS
$25.9M 6.45%
614,812
+193,590
+46% +$9.3M
2023 Q4
4 quarters
CRNX icon
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$16.2M 4.05%
317,060
+103,245
+48% +$5.78M
2023 Q4
4 quarters
XENE icon
6
Xenon Pharmaceuticals
XENE
$3.64B
$14.7M 3.68%
+375,845
New +$15.5M
2024 Q4
0 quarters
INCY icon
7
Incyte
INCY
$23.4B
$13.4M 3.34%
193,623
+64,133
+50% +$4.57M
2024 Q3
1 quarter
ALKS icon
8
Alkermes
ALKS
$7.55B
$12M 2.99%
416,968
+368,050
+752% +$10.6M
2024 Q3
1 quarter
DNLI icon
9
Denali Therapeutics
DNLI
$2.96B
$11.9M 2.97%
584,328
+302,278
+107% +$7.74M
2024 Q2
2 quarters
RYTM icon
10
Rhythm Pharmaceuticals
RYTM
$7.79B
$11.6M 2.91%
208,016
+166,748
+404% +$9.21M
2024 Q3
1 quarter
NUVL icon
11
DELISTED
Nuvalent
NUVL
$11.4M 2.84%
+145,234
New +$13.6M
2024 Q4
0 quarters
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$10.8M 2.68%
641,964
+558,302
+667% +$9.25M
2024 Q3
1 quarter
PRAX icon
13
Praxis Precision Medicines
PRAX
$8.4B
$10.3M 2.58%
134,178
-39,856
-23% -$2.88M
2024 Q1
3 quarters
BMY icon
14
Bristol-Myers Squibb
BMY
$120B
$9.39M 2.34%
166,068
-109,235
-40% -$6.1M
2024 Q3
1 quarter
WVE icon
15
Wave Life Sciences
WVE
$505M
$8.92M 2.23%
721,209
+421,209
+140% +$5.62M
2024 Q3
1 quarter
RVMD icon
16
Revolution Medicines
RVMD
$34.9B
$8.47M 2.11%
193,535
+176,881
+1,062% +$8.93M
2024 Q3
1 quarter
KALV icon
17
DELISTED
KalVista Pharmaceuticals
KALV
$8.41M 2.1%
+992,803
New +$10.3M
2024 Q4
0 quarters
JANX icon
18
Janux Therapeutics
JANX
$617M
$7.81M 1.95%
145,876
+96,461
+195% +$5.1M
2024 Q1
3 quarters
INSM icon
19
Insmed
INSM
$31B
$7.36M 1.84%
+106,610
New +$7.68M
2024 Q4
0 quarters
SRRK icon
20
Scholar Rock
SRRK
$5.87B
$7.19M 1.79%
+166,307
New +$5.42M
2024 Q4
0 quarters
IOVA icon
21
Iovance Biotherapeutics
IOVA
$3.19B
$7.03M 1.75%
+949,401
New +$8.8M
2024 Q4
0 quarters
BNTX icon
22
BioNTech
BNTX
$20.1B
$7M 1.75%
+61,403
New +$7.01M
2024 Q4
0 quarters
ARQT icon
23
Arcutis Biotherapeutics
ARQT
$3.33B
$6.98M 1.74%
500,966
-1,277,352
-72% -$14M
2023 Q4
4 quarters
BHVN icon
24
Biohaven
BHVN
$1.87B
$6.96M 1.74%
186,413
-30,027
-14% -$1.4M
2023 Q4
4 quarters
VTGN icon
25
VistaGen Therapeutics
VTGN
$7.56M
$5.95M 1.48%
2,328,492
+481,700
+26% +$1.36M
2023 Q4
4 quarters

Similar funds

Stempoint Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Stempoint Capital held 80 positions worth $401M, up 20% from $334M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $95.5M of net new capital in Q4 2024, opening 26 new positions and adding to 21 existing holdings. Its largest new stake was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $14M trimmed.

  • Stempoint Capital's largest Q4 2024 buy was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.
  • Stempoint Capital added most to Syndax Pharmaceuticals in Q4 2024, an estimated $19.5M increase.
  • Stempoint Capital's biggest Q4 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $14M.
  • Stempoint Capital fully exited Amicus Therapeutics in Q4 2024, selling an estimated $15.8M.
  • Stempoint Capital's ten largest holdings make up 51% of its $401M portfolio in Q4 2024.
  • Stempoint Capital opened 26 new positions and closed 26 in Q4 2024.
  • Stempoint Capital's portfolio value rose 20% quarter-over-quarter to $401M.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.